Superluminal Medicines Raises $60M Series B to Advance Obesity Drug – Unite.AI

Superluminal Medicines, a Boston biotechnology company applying AI and machine learning to drug discovery, announced on September 3, 2026 the closing of an oversubscribed $60 million Series B financing. BVF Partners, L.P. led the round, which the company said will advance its lead program for rare genetic forms of obesity toward a first clinical trial.

The company announced the financing through its official news release. According to the announcement, proceeds will support the initiation of a Phase 1 clinical trial in rare, genetic forms of obesity by the end of 2026, as well as continued expansion of the company’s GPCR-focused discovery platform.

Financing and Investor Syndicate

New investors Deep Track Capital and Perceptive Advisors joined the round, alongside existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. The company described the financing as oversubscribed.

Cony D’Cruz, Chief Executive Officer of Superluminal Medicines, said the financing marked the company’s transition from a discovery platform company to a clinical-stage biotechnology company. D’Cruz said rare genetic forms of obesity and hypothalamic obesity are devastating diseases with limited treatment options, and said the company’s selective, biased MC4R agonist has the potential to make a meaningful difference for these patients.

Harsha Paladugu, Investment Analyst at BVF and a member of Superluminal’s Board of Directors, said the lead MC4R program has the potential to address a serious unmet need for patients with rare genetic forms of obesity. Paladugu said the company’s integrated discovery platform has demonstrated the ability to generate differentiated small molecule medicines against historically challenging GPCR targets.

Nandita Shangari, managing director at RA Capital Management and a member of Superluminal’s Board of Directors, said the caliber of the financing syndicate reflects the progress the company has made in establishing a differentiated approach to small molecule drug discovery.

Lead Program and Pipeline

Superluminal’s lead clinical program is a selective, biased MC4R agonist being developed for rare genetic forms of obesity and hypothalamic obesity. The company said a Phase 1 clinical trial is expected to begin by the end of 2026.

The MC4R pathway is a clinically validated regulator of energy homeostasis and appetite, with established relevance in rare genetic forms of obesity, including Bardet-Biedl syndrome (BBS) and hypothalamic obesity. The company said that because MC4R signaling plays an important role in many metabolic conditions, the program may have future applications in rare diseases such as Prader-Willi syndrome, as well as in the broader population in combination with GLP-1 therapies. The company said its approach is designed to maximize therapeutic activity while minimizing side effects by activating only the signaling pathways responsible for the desired clinical effect, and said the candidate demonstrated high selectivity and a favorable safety profile in preclinical studies.

Discovery Platform

Superluminal has integrated advanced structural biology with proprietary machine learning tools to accelerate the discovery of candidate-ready small molecules. The platform combines Agentic Cryo-EM capabilities, which enable the generation of hundreds of empirical GPCR structures, with GPCR-focused co-folding models, de novo small-molecule design across diverse 3D pocket conformations, predictive ADME/toxicology models, and novel GPCR biophysics. The company said these capabilities form the foundation of its next-generation R&D engine.

In addition to its wholly owned pipeline, Superluminal continues to advance strategic collaborations with pharmaceutical partners, including a partnership with Eli Lilly and Company to advance small molecule therapeutics targeting undisclosed GPCRs for cardiometabolic diseases and obesity.

The Series B follows a $120 million Series A financing that the company closed on September 9, 2024, led by RA Capital Management. The company also previously announced on August 14, 2025 a collaboration with Eli Lilly and Company under which Superluminal is eligible to receive up to $1.3 billion, including upfront and near-term payments, an equity investment, development and commercial milestones, and tiered royalties on net sales.